Q2 earnings underway, FDA’s CRL kerfuffle, IPOs full speed ahead in H2

The biopharma industry enters a busy second-quarter earnings season, with major players like AbbVie, Amgen, and Eli Lilly under scrutiny for their recent acquisitions and product launches. Eli Lilly’s multi-billion dollar investment in Atai Life Sciences signals significant validation for the psychedelic medicine sector, specifically for treatment-resistant depression. Meanwhile, the FDA’s controversial initiative to publish complete response letters in real-time faces legal challenges and operational hurdles regarding redaction and transparency. Public markets show renewed vitality, as the number of biotech IPOs in the first half of the year has already surpassed previous annual totals. Despite this growth, the industry remains cautious about the performance of earlier-stage companies compared to the record-breaking, later-stage debuts seen earlier this year. AstraZeneca continues to pursue an ambitious $80 billion revenue goal by 2030, despite recent clinical trial setbacks for its drug Wainua.